Phaseline

Companies › Bristol-Myers Squibb

Bristol-Myers Squibb: clinical trials, targets and expected readouts

70 active drug programs in 1064 registered trials: 571 Phase 2, 336 Phase 1, 135 Phase 3, 22 Phase 4; Oncology, Immunology, Neurology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trospium Chloride
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Schizophrenia; Bipolar-I Disorder With Mania or Mania With Mixed Features; Bipolar Disorder Type I With Mania or Mania With Mixed Features; Mania …Nov 2026
Deucravacitinib
Tyrosine-protein kinase TYK2 negative allosteric modulator
TYK2Phase 4Systemic Lupus Erythematosus (SLE); Psoriatic Arthritis; Sjögren's Syndrome; Systemic Lupus Erythematosus …Nov 2026
Trospium Chloride (BMS-986510)
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM2Phase 4Healthy Volunteers; Psychosis Associated With Alzheimer's Disease; Alzheimer Disease; SchizophreniaNov 2026
Mavacamten (BMS-986427)
Cardiac myosin inhibitor
MYH7, MYH6, MYH7B, MYL3, MYL2Phase 4Cardiomyopathy, Hypertrophic; Symptomatic Obstructive Hypertrophic CardiomyopathyJun 2027
Luspatercept (ACE-536)
Transforming growth factor beta inhibitor
TGFB1, TGFB2, TGFB3Phase 4Anemia; Myelodysplastic Syndromes; Beta-thalassemia; CCUS Clonal Cytopenia of Undetermined Significance …Jul 2027
Ozanimod
Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor 5 modulator
S1PR1, S1PR5Phase 4Relapsing Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative; Alzheimer DiseaseDec 2028
Adagrasib
GTPase KRas inhibitor
KRASPhase 3Metastatic Non Small Cell Lung Cancer; Advanced Colorectal Cancer; Carcinoma, Non-Small-Cell Lung; Advanced Cancer …Nov 2026
CC-92480 (BMS-986348, mezigdomide)
Cereblon E3 ligase modulator (cereblon-binding protein that promotes IKZF1 and IKZF3 degra
CRBNPhase 3Relapsed or Refractory Multiple Myeloma; Multiple MyelomaNov 2026
Nivolumab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Urothelial Cancer; Melanoma; Renal Cell Carcinoma; Metastatic Colorectal Cancer …Nov 2026
Relatlimab
Lymphocyte activation gene 3 protein inhibitor
LAG3Phase 3Non-small Cell Lung Cancer; Melanoma; Cancer; Urologic Neoplasms …Dec 2026
Ipilimumab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 3Urothelial Cancer; Renal Cell Carcinoma; Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer …Feb 2027
Repotrectinib
Nerve growth factor receptor Trk-A inhibitor; Neurotrophic tyrosine kinase receptor type 2 inhibitor; Proto-oncogene tyrosine-protein kinase ROS inhibitor
NTRK1, NTRK2, ROS1, NTRK3, CD74Phase 3Carcinoma, Non-Small-Cell LungFeb 2027
Xanomeline
Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM4, CHRM1Phase 3Alzheimer Disease; Alzheimer's Disease; Healthy Volunteers; SCHIZOPHRENIA 1 (Disorder)Mar 2027
Golcadomide (CC-99282, BMS-986369)
Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader
CRBN, IKZF1, IKZF3Phase 3Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin …Apr 2027
BMS-986278
LOXL2 inhibitor
LOXL2Phase 3Idiopathic Pulmonary Fibrosis; Progressive Pulmonary FibrosisJun 2027
Abatacept
T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor
CD86, CD80Phase 3Rheumatoid Arthritis; Myocarditis Acute; Polyarticular Course Juvenile Idiopathic Arthritis (JIA); Biphenotypic Acute Leukemia …Sep 2027
BMS-986365
Androgen receptor degrader (PROTAC)
–Phase 3Metastatic Castration-resistant Prostate CancerSep 2027
Luspatercept (ACE-536)
Transforming growth factor beta inhibitor
TGFB1, TGFB2, TGFB3Phase 3Myelodysplastic Syndromes; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders; Beta-ThalassemiaSep 2027
Iberdomide
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 3Multiple Myeloma; Lymphoma, B-Cell; Newly Diagnosed Multiple Myeloma; Smoldering Plasma Cell Myeloma …Nov 2027
BMS-986393 (Arlocabtagene autoleucel, arlo-cel)–Phase 3Relapsed or Refractory Multiple Myeloma (RRMM); Multiple MyelomaDec 2027
BMS-986507 (Iza-bren, Izalontamab brengitecan)–Phase 3Non-Small Cell Lung Cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Urothelial Cancer …Mar 2028
Rituximab
B-lymphocyte antigen CD20 binding agent
MS4A1Phase 3Follicular LymphomaApr 2028
Pumitamig (BMS-986545, BNT327, PM8002)–Phase 3Non-small Cell Lung Cancer (NSCLC); Non-Small Cell Lung Cancer (NSCLC); Solid Tumors; Locally Advanced Non-Small Cell Lung Cancer (NSCLC) …Jul 2028
Mezigdomide
Cereblon E3 ubiquitin ligase modulator (CRBN modulator)
CRBNPhase 3Relapsed or Refractory Multiple MyelomaJul 2029
idecabtagene vicleucel
Tumor necrosis factor receptor superfamily member 17 binding agent
TNFRSF17Phase 3Multiple MyelomaNov 2029
Xanomeline (BMS-986519)
Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist
CHRM4, CHRM1Phase 3SchizophreniaMar 2030
Belatacept
T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor
CD86, CD80Phase 3Renal Allograft Recipients; Kidney Diseases; Chronic Kidney Failure; Heart Transplantation …Dec 2032
Navlimetostat (BMS-986504)
Selective, MTA-cooperative PRMT5 inhibitor
PRMT5, MTAPPhase 2Solid Tumors; Pancreatic Ductal Adenocarcinoma; Healthy Participants; Healthy Female Participants …Nov 2026
BMS-986435–Phase 2Heart Failure; Healthy VolunteersDec 2026
BMS-986446
Anti-microtubule-binding region (MTBR) tau monoclonal antibody
MAPTPhase 2Alzheimer Disease, Early Onset; Alzheimer's DiseaseDec 2026
Irafamdastat (BMS-986368, CC-97489)
FAAH/MAGL inhibitor
FAAH, MAGLPhase 2Multiple Sclerosis Spasticity; Agitation; Healthy VolunteersDec 2026
BMS-986504 (MRTX1719)
Selective MTA-cooperative inhibitor of PRMT5
MTAP, PRMT5Phase 2Carcinoma, Non-Small-Cell Lung; Metastatic Non-small Cell Lung Cancer With MTAP Deletion; Advanced Solid Tumors; Advanced Solid Tumors With Homozygous MTAP Deletion …Jan 2027
CC-97540
CD19-targeted CAR T cells
CD19Phase 2Lupus Erythematosus, Systemic; Multiple Sclerosis; Systemic Lupus Erythematosus; Antineutrophil Cytoplasmic Antibody-associated VasculitisJul 2027
Lisocabtagene Maraleucel
B-lymphocyte antigen CD19 binding agent
CD19Phase 2LymphomaJan 2028
Azacitidine (BMS-986345)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 2Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Angioimmunoblastic T-cell Lymphoma (AITL) …Jul 2028
Daraxonrasib (RMC-6236)
KRAS inhibitor
KRASPhase 2Solid TumorsAug 2028
Imzokitug
Anti-CCR8 monoclonal antibody
CCR8Phase 2Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Pancreatic AdenocarcinomaSep 2028
Lisocabtagene Maraleucel (JCAR017)
B-lymphocyte antigen CD19 binding agent
CD19Phase 2Lymphoma, Non-HodgkinSep 2031
Gene-modified T cell therapy–Phase 2NeoplasmsMay 2043
BMS-986521
M4 muscarinic acetylcholine receptor antagonist
CHRM4Phase 1Healthy VolunteersNov 2026
CC-122 (also: Avadomide, BMS-986381)
Cereblon E3 ligase modulator
CRBNPhase 1Non-Hodgkin LymphomaNov 2026
Fedratinib
Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
FLT3, JAK2Phase 1Primary Myelofibrosis; Acute Myeloid LeukemiaNov 2026
Golcadomide (BMS-986369, CC-99282)
Cereblon (CRBN) E3 ligase modulator
CRBNPhase 1Kidney Failure, Chronic; Relapsed/Refractory Non-Hodgkin Lymphoma; Relapsed or Refractory T-cell LymphomasDec 2026
BMS-986470
P-selectin antagonist
–Phase 1Anemia, Sickle CellJan 2027
BMS-986533–Phase 1Healthy VolunteersJun 2027
BMS-986454–Phase 1Rheumatoid ArthritisJun 2027
BMS-986484–Phase 1Advanced Solid TumorsOct 2027
BMS-986488–Phase 1Advanced Malignant TumorsOct 2027
BMS-986458
cereblon-dependent ligand-directed degrader of BCL6
BCL6Phase 1Relapsed/Refractory Non-Hodgkin LymphomaOct 2027
Lisocabtagene Maraleucel (JCAR017)
B-lymphocyte antigen CD19 binding agent
CD19Phase 1Leukemia, Lymphocytic, Chronic, B-Cell; Recurrent Transformed Chronic Lymphocytic Leukemia; Lymphoma; Refractory Aggressive B-cell Lymphomas …Nov 2027
BMS-986517–Phase 1Solid TumoursJul 2028
Alnuctamab (BMS-986349, CC-93269, EM901)
GPRC5D-targeting monoclonal antibody
GPRC5DPhase 1Multiple Myeloma; Systemic Lupus ErythematosusAug 2028
Iberdomide (BMS-986382)
CRL4(CRBN) E3 ubiquitin ligase modulator
CRBN, DDB1, CUL4A, RBX1Phase 1Multiple MyelomaAug 2028
Mezigdomide (BMS-986348, CC-92480)
Cereblon E3 ubiquitin ligase modulator
CRBNPhase 1Multiple Myeloma; Extramedullary Disease in Multiple Myeloma; KMT2A-rearranged; Relapsed Refractory Multiple Myeloma (RRMM) …Aug 2028
Ezobresib (BMS-986158)
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 1Multiple Myeloma; MyelofibrosisAug 2028
BMS-986523–Phase 1Advanced Solid MalignanciesOct 2028
BMS-986500–Phase 1Advanced Solid TumorDec 2028
BMS-986463–Phase 1High-grade Serous Ovarian Carcinoma (HGSOC)Dec 2028
BMS-986482–Phase 1Advanced Solid TumorsJan 2029
BMS-986515
CD19-targeted allogeneic CAR T cell therapy
CD19Phase 1Refractory Autoimmune DiseasesMar 2029
BMS-986525–Phase 1Relapsed/Refractory Small Cell Lung CancerApr 2029
BMS-986460–Phase 1Metastatic Castration-resistant Prostate CancerAug 2029
BMS-986528–Phase 1Arthritis, RheumatoidOct 2029
BMS-986490
anti-CEACAM5 antibody
CEACAM5Phase 1Advanced Solid TumorsDec 2029
BMS-986453
BCMA-directed CAR-T cell therapy
–Phase 1Relapsed and/or Refractory Multiple Myeloma; Multiple MyelomaMay 2030
BMS-986506–Phase 1Renal Cell CarcinomaMay 2030
BMS-986340
PRMT5 inhibitor
–Phase 1Cervical CancerAug 2031
BMS-986449–Phase 1Advanced Solid Tumors–
Enasidenib (AG-221)
Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
IDH2Phase 1Leukemia, Myeloid, Acute; Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Myelodysplastic Syndromes …–
Ivosidenib (AG-120)
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 1Leukemia, Myeloid, Acute–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02677922Ivosidenib (AG-120)Phase 1Leukemia, Myeloid, AcuteOncologyAug 2018
NCT02677922Enasidenib (AG-221)Phase 1Leukemia, Myeloid, AcuteOncologyAug 2018
NCT02632708Enasidenib (AG-221)Phase 1Newly Diagnosed Acute Myeloid Leukemia (AML)HematologyDec 2018
NCT02656706NivolumabPhase 2MelanomaOncologyMar 2019
NCT02656706IpilimumabPhase 2MelanomaOncologyMar 2019
NCT02758717NivolumabPhase 2Ann Arbor Stage IB Hodgkin LymphomaOncologyAug 2019
NCT03350126NivolumabPhase 2Metastatic Cancer ColorectalOncologyJan 2020
NCT03350126IpilimumabPhase 2Metastatic Cancer ColorectalOncologyJan 2020
NCT03452579NivolumabPhase 2GlioblastomaOncologyDec 2020
NCT03341936NivolumabPhase 2Squamous Cell Carcinoma of the Head and NeckOncologyJul 2021
NCT03071406NivolumabPhase 2Merkel Cell CarcinomaOncologyApr 2022
NCT03071406IpilimumabPhase 2Merkel Cell CarcinomaOncologyApr 2022
NCT02743819IpilimumabPhase 2MelanomaOncologyJun 2022
NCT03241186NivolumabPhase 2Mucosal MelanomaOncologySep 2022
NCT03241186IpilimumabPhase 2Mucosal MelanomaOncologySep 2022
NCT04361162NivolumabPhase 2Pancreatic CancerOncologyOct 2022
NCT04361162IpilimumabPhase 2Pancreatic CancerOncologyOct 2022
NCT03161223Azacitidine (BMS-986345)Phase 1Lymphoma, T-CellOncologyFeb 2023
NCT03038672NivolumabPhase 2ALK-Positive Large B-Cell LymphomaOncologyMay 2023
NCT03377023NivolumabPhase 1Non Small Cell Lung CancerOncologyNov 2023
NCT03377023IpilimumabPhase 1Non Small Cell Lung CancerOncologyNov 2023
NCT03443856NivolumabPhase 2Gastric and Esophagogastric Junction AdenocarcinomaOncologyDec 2023
NCT03443856IpilimumabPhase 2Gastric and Esophagogastric Junction AdenocarcinomaOncologyDec 2023
NCT04575922NivolumabPhase 2Metastatic Microsatellite Stable Colorectal CancerOncologyDec 2023
NCT04575922IpilimumabPhase 2Metastatic Microsatellite Stable Colorectal CancerOncologyDec 2023
NCT05182957Azacitidine (BMS-986345)Phase 2Relapsed/Refractory Peripheral T-cell LymphomaOncologyDec 2023
NCT04685135AdagrasibPhase 3Metastatic Non Small Cell Lung CancerOncologyDec 2023
NCT03480334NivolumabPhase 2Classical Hodgkin LymphomaOncologyMay 2024
NCT04195139NivolumabPhase 2Glioblastoma MultiformeOncologyJun 2024
NCT03036098NivolumabPhase 3Urothelial CancerOncologyAug 2024
NCT03036098IpilimumabPhase 3Urothelial CancerOncologyAug 2024
NCT05401786IpilimumabPhase 2Carcinoma, Non-Small-Cell LungOncologyNov 2024
NCT02648997NivolumabPhase 2MeningiomasOncologyDec 2024
NCT02648997IpilimumabPhase 2MeningiomasOncologyDec 2024
NCT04003649NivolumabPhase 1Recurrent GlioblastomaOncologyDec 2024
NCT04003649IpilimumabPhase 1Recurrent GlioblastomaOncologyDec 2024
NCT05197426Azacitidine (BMS-986345)Phase 2Acute Myeloid LeukemiaOncologyJan 2025
NCT04905810Azacitidine (BMS-986345)Phase 2Acute Myeloid LeukemiaOncologyMay 2025
NCT05480384NivolumabPhase 2Esophageal AdenocarcinomaOncologyMay 2025
NCT02914405NivolumabPhase 1NeuroblastomaOncologyJun 2025
NCT04126070NivolumabPhase 2Hormone Sensitive Prostate CancerOncologyJul 2025
NCT05567458Luspatercept (ACE-536)Phase 2Beta-thalassemiaHematologyAug 2025
NCT04203316Enasidenib (AG-221)Phase 2Recurrent Acute Myeloid LeukemiaOncologySep 2025
NCT04006262NivolumabPhase 2Localized Oesogastric AdenocarcimonaOncologyOct 2025
NCT04006262IpilimumabPhase 2Localized Oesogastric AdenocarcimonaOncologyOct 2025
NCT05595447NivolumabPhase 2Hodgkin LymphomaOncologyOct 2025
NCT05413018Azacitidine (BMS-986345)Phase 2Leukemia, Myeloid, AcuteOncologyOct 2025
NCT04803877NivolumabPhase 2OsteosarcomaOncologyNov 2025
NCT05833438Azacitidine (BMS-986345)Phase 2Acute Myeloid Leukemia (AML)OncologyNov 2025
NCT03670056NivolumabPhase 2Small Cell Lung CancerOncologyDec 2025
NCT05598853NivolumabPhase 1Leptomeningeal MetastasisOncologyDec 2025
NCT03670056IpilimumabPhase 2Small Cell Lung CancerOncologyDec 2025
NCT05598853IpilimumabPhase 1Leptomeningeal MetastasisOncologyDec 2025
NCT05325099Azacitidine (BMS-986345)Phase 1Acute Kidney DiseaseGenitourinaryDec 2025
NCT04793958AdagrasibPhase 3Advanced Colorectal CancerOncologyJan 2026
NCT04184505Azacitidine (BMS-986345)Phase 3High-risk MDSOncologyMar 2026
NCT05901974Azacitidine (BMS-986345)Phase 2Acute Leukemia of Ambiguous LineageOncologyMar 2026
NCT05732961Luspatercept (ACE-536)Phase 2Myelodysplastic SyndromesHematologyMar 2026
NCT04295863NivolumabPhase 1Metastatic CancerOncologyApr 2026
NCT04400539NivolumabPhase 2Mesotheliomas PleuralOncologyMay 2026

The 60 nearest readouts of 1064 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $12.6bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CRBN (8) CD19 (5) CHRM4 (3) CHRM3 (2) CHRM2 (2) CHRM1 (2) KRAS (2) DDB1 (2) CUL4A (2) RBX1 (2) PRMT5 (2) MTAP (2)

Companies with the same targets

AstraZeneca Gilead Sciences Chongqing Precision Biotech Roche Allogene Therapeutics Miltenyi Biomedicine Novartis Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ocus Innovation Ireland Incyte

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.